Organogenesis (NASDAQ:ORGO) Shares Gap Up – What’s Next?

Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) gapped up prior to trading on Tuesday . The stock had previously closed at $5.42, but opened at $5.56. Organogenesis shares last traded at $5.20, with a volume of 239,503 shares.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley increased their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Stock Performance

The stock has a market cap of $658.87 million, a P/E ratio of -86.47 and a beta of 1.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company has a fifty day moving average of $4.09 and a 200 day moving average of $3.53.

Insider Transactions at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 36.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors acquired a new stake in shares of Organogenesis during the 3rd quarter valued at $36,000. Virtu Financial LLC acquired a new stake in shares of Organogenesis during the fourth quarter worth $38,000. Intech Investment Management LLC purchased a new stake in shares of Organogenesis during the third quarter valued at $43,000. Palumbo Wealth Management LLC acquired a new position in shares of Organogenesis in the 4th quarter valued at $65,000. Finally, ProShare Advisors LLC increased its stake in Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after purchasing an additional 6,689 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.